The company is hoping longer follow-up will deliver enough positive trial data on its CRISPR T-cell therapies for blood ...

Crispr Therapeutics is an emerging gene editing company focused on the development of Crispr/Cas9-based therapeutics. The company's proprietary platform specializes in clustered regularly interspaced ...

Latest study leverages new constructs for nuclear localization signal (NLS) sequences to improve editing efficiency in human ...

The Global Cell And Gene Therapy Market is valued at USD 20.5 Billion in 2024 and is projected to reach a value of USD 128.8 ...

Strategic pipeline prioritization with workforce and cost reductions expected to extend the company's cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 ...

Strategic pipeline prioritization with workforce and cost reductions expected to extend the company’s cash runway by one year into H2 2027 -- -- Two robust clinical datasets from CB-010 and CB-011 now ...

Bristol Myers Squibb’s new treatment for schizophrenia didn’t provide additional benefits to patients when given on top of ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

Biomedical Research leads at USD 1.5 billion, supporting genetic discovery and translational research.

Developments in genomics are enabling the rise of personalised medicine, with therapies tailored specifically for individuals ...